Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWitching InflixiMab to SUbcut from Intravenous Therapy
2020-004463-25Phase 4Unknown
- Sponsor
- University Hospital Southampton
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis, rheumatoid arthritis (RA) and 2 more, sponsored by University Hospital Southampton. Primary endpoint: Maintenance of baseline clinical status at week 24. Status: unknown.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisrheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2020-004463-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004463-25.